Ultragenyx’s GENGLYCOS Becomes First FDA-Approved Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx’s GENGLYCOS receives accelerated FDA approval as the first gene therapy targeting the root cause of GSDIa in patients aged 8 and older.